Exagen (XGN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Executive summary
Annual meeting scheduled for June 9, 2026, at the company's Carlsbad, California offices.
Stockholders of record as of April 15, 2026, are eligible to vote on key proposals.
Proxy materials are available online, with options to request paper or email copies.
Voting matters and shareholder proposals
Election of two Class I directors, Tina S. Nova, Ph.D., and Scott D. Kahn, Ph.D., for three-year terms expiring in 2029.
Ratification of BDO USA, P.C. as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote to approve executive compensation as disclosed in the proxy statement.
Board recommends voting FOR all director nominees and proposals.
Board of directors and corporate governance
Board recommends the election of two directors to serve until the 2029 annual meeting and until successors are elected.
Latest events from Exagen
- $50m ATM offers flexible capital, with illustrative dilution of $3.98/share at $5.81.XGN
Registration filing - Record Q3 revenue and stronger 9M adjusted EBITDA support reiterated FY guidance.XGN
Q3 2026 - Record FY revenue and higher margins, with 2024 guidance targeting continued progress.XGN
Q4 2023 - Improved reimbursement and operational focus drive growth, with new products fueling future expansion.XGN
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 revenue up 16%, margins improved, losses narrowed, and guidance raised.XGN
Q2 2026 - Record Q1 2026 revenue, higher ASP, and strong cash position support positive full-year outlook.XGN
Q1 2026 - Shareholders will vote on director elections, auditor ratification, and executive pay, with board support for all.XGN
Proxy filing - 2025 revenue rose 20% to $66.6M, with improved margins and strong AVISE CTD test growth.XGN
Q4 2025 - Record revenue, margin expansion, and new biomarkers set up strong growth for 2025.XGN
Q4 2024